Palvella Therapeutics, Inc. (FRA:PI6)

Germany flag Germany · Delayed Price · Currency is EUR
69.00
-4.00 (-5.48%)
Last updated: Jan 28, 2026, 8:02 AM CET
470.25%
Market Cap764.05M +426.7%
Revenue (ttm)n/a
Net Income-27.59M
EPS-3.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume7
Open69.00
Previous Close73.00
Day's Range69.00 - 69.00
52-Week Range11.80 - 94.00
Betan/a
RSI38.28
Earnings DateMar 31, 2026

About Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Way... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Wesley Kaupinen
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PI6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements